PUBLISHER: Azoth Analytics | PRODUCT CODE: 1148863
PUBLISHER: Azoth Analytics | PRODUCT CODE: 1148863
Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)
Executive Summary
According to Azoth Analytics research report, the Alzheimer's disease Therapeutics- Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.
The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease.
Alzheimer's prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades.
Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario.
Scope of the Report
- The report analyses the Alzheimer's Disease Therapeutics in the Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others).
- The report analyses Alzheimer's disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other).
- The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).
- The Alzheimer's Disease Therapeutics- Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
- The key insights of the report have been presented through the leading company shares.
- Also, the major trends, drivers and challenges as well as unmet needs of the industry has been analysed in the report.
- The companies analysed in the report include Eli-Lily & Co, Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen.
Key Target Audience
- Alzheimer's Disease Therapeutics Companies
- End Users (Hospitals and clinics)
- Research and Development (R&D) Organizations
- Government Bodies & Regulating Authorities
- Investment Banks and Equity Firms
Table of Contents
1. Introduction
- 1.1 Alzheimer's Disease Therapeutics Overview
- 1.2 Scope of Research
2. Executive Summary
- 2.1 Market Dashboard
- 2.2 Regional Insights
- 2.3 Market Ecosystem Factors
3. Research Methodology
- 3.1 Data Collection Process
- 3.2 Market Size Calculation-Top-to-Bottom
4. Macro Economic Indicator Outlook
- 4.1 Global, Region-wise GDP Growth
- 4.2 Global Medical Spending
- 4.3 Current Healthcare Expenditure
- 4.4 Pharmaceutical Spending/capita
5. Competitive Positioning
- 5.1 Companies - Product Positioning
- 5.2 Competitive positioning
- 5.2.1 Eli-Lily & Co
- 5.2.2 Elsal Co., Ltd.
- 5.2.3 BioVie
- 5.2.4 Johnson & Johnson
- 5.2.5 Otsuka Pharmaceutical Co., Ltd.
- 5.2.6 H. Lundbeck A/S
- 5.2.7 Novartis
- 5.2.8 Cognition Therapeutics
- 5.2.9 Merck Sharp & Dohme LLC
- 5.2.10 Biogen
6. Alzheimer's disease background
- 6.1 AD Fact Sheet
- 6.2 Epidemiology
- 6.3 Causes and Risk Factors
- 6.4 Diagnosis and Assessment
- 6.5 Unmet Needs
7. Therapeutics in Pipeline
- 7.1 Pipeline Scenario
- 7.2 Alzheimer's Therapeutics Comparative Review
8. Pipeline Analysis
9. Phase I therapeutics Overview
- 9.1 LY3372993
- 9.1.1 Drug Description
- 9.1.2 Outcomes
- 9.2 Lu AF87908
- 9.2.2 Drug Description
- 9.2.3 Outcomes
- 9.3 anle138b
- 9.3.1 Drug Description
- 9.3.2 Outcomes
- 9.3.3 Collaborators
- 9.4 ASN51
- 9.4.1 Drug Description
- 9.4.2 Outcomes
- 9.4.3 Collaborators
- 9.5 CMS121
- 9.5.1 Drug Description
- 9.5.2 Outcomes
- 9.5.3 Collaborators
- 9.6 IBC-Ab002
- 9.6.1 Drug Description
- 9.6.2 Outcomes
- 9.6.3 Collaborators
- 9.7 LX1001
- 9.7.1 Drug Description
- 9.7.2 Outcomes
- 9.8 MK-2214
- 9.8.1 Drug Description
- 9.8.2 Outcomes
- 9.9 MK-8189
- 9.9.1 Drug Description
- 9.9.2 Outcomes
- 9.10 ACU193
- 9.10.1 Drug Description
- 9.10.2 Outcomes
- 9.10.3 Collaborators
- 9.11 NIO752
- 9.11.1 Drug Description
- 9.11.2 Outcomes
- 9.12 ALN-APP
- 9.12.1 Drug Description
- 9.12.2 Outcomes
- 9.13 TB006
- 9.13.1 Drug Description
- 9.13.2 Outcomes
- 9.14 SNK01
- 9.14.1 Drug Description
- 9.14.2 Outcomes
- 9.15 Pepinemab
- 9.15.1 Drug Description
- 9.15.2 Outcomes
- 9.15.3 Collaborators
- 9.16 GB-5001
- 9.16.1 Drug Description
- 9.16.2 Outcomes
- 9.17 AC-1202
- 9.17.1 Drug Description
- 9.17.2 Outcomes
- 9.18 SHR-1707
- 9.18.1 Drug Description
- 9.18.2 Outcomes
- 9.19 BEY2153
- 9.19.1 Drug Description
- 9.19.2 Outcomes
- 9.20 JNJ-40346527
- 9.20.1 Drug Description
- 9.20.2 Outcomes
- 9.20.3 Collaborators
- 9.21 APNmAb005
- 9.21.1 Drug Description
- 9.21.22 Outcomes
- 9.22 NPT 2042
- 9.22.1 Drug Description
- 9.22.2 Outcomes
- 9.23 ALZ-101
- 9.23.1 Drug Description
- 9.23.2 Outcomes
10. Phase I/II therapeutics Overview
- 10.1 Posiphen
- 10.1.1 Drug Description
- 10.1.2 Outcomes
- 10.1.3 Collaborators
- 10.2 PrimeProo/ PrimeMSKo
- 10.2.1 Drug Description
- 10.2.2 Outcomes
- 10.2.3 Collaborators
- 10.3 TB006
- 10.3.1 Drug Description
- 10.3.2 Outcomes
- 10.4 RO7126209
- 10.4.1 Drug Description
- 10.4.2 Outcomes
- 10.5 DNL593
- 10.5.1 Drug Description
- 10.5.2 Outcomes
- 10.5.3 Collaborators
- 10.6 BIIB080
- 10.6.1 Drug Description
- 10.6.1 Outcomes
- 10.7 E2814
- 10.7.1 Drug Description
- 10.7.2 Outcomes
- 10.8 Tdap
- 10.8.1 Drug Description
- 10.8.2 Outcomes
- 10.8.3 Collaborators
- 10.9 ACI-35.030/ JACI-35.054
- 10.9.1 Drug Description
- 10.9.2 Outcomes
- 10.9.3 Collaborators
- 10.10 ACI-24.060
- 10.10.1 Drug Description
- 10.10.2 Outcomes
- 10.10.3 Collaborators
- 10.11 IVL3003
- 10.10.1 Drug Description
- 10.10.2 Outcomes
11. Phase II therapeutics Overview
- 11.1 Lecanemab
- 11.1.1 Drug Description
- 11.1.2 Outcomes
- 11.1.3 Collaborators
- 11.2 Lomecel-B
- 11.2.1 Drug Description
- 11.2.2 Outcomes
- 11.2.3 Collaborators
- 11.3 AL002
- 11.3.1 Drug Description
- 11.3.2 Outcomes
- 11.3.3 Collaborators
- 11.4 AL001
- 11.4.1 Drug Description
- 11.4.2 Outcomes
- 11.5 CT1812 (Elaya)
- 11.5.1 Drug Description
- 11.5.2 Outcomes
- 11.6 APH-1105
- 11.6.1 Drug Description
- 11.6.2 Outcomes
- 11.7 ATH-1017
- 11.7.1 Drug Description
- 11.7.2 Outcomes
- 11.8 T-817MA
- 11.8.1 Drug Description
- 11.8.2 Outcomes
- 11.9 Montelukast buccal film
- 11.9.1 Drug Description
- 11.9.2 Outcomes
- 11.10 ABBV-916
- 11.10.1 Drug Description
- 11.10.2 Outcomes
- 11.11 Bepranemab
- 11.11.1 Drug Description
- 11.11.2 Outcomes
- 11.12 TB006
- 11.12.1 Drug Description
- 11.12.2 Outcomes
- 11.13 LY3372689
- 11.13.1 Drug Description
- 11.13.2 Outcomes
- 11.14 MW150
- 11.14.1 Drug Description
- 11.14.2 Outcomes
- 11.14.3 Collaborators
- 11.15 EX039
- 11.15.1 Drug Description
- 11.15.2 Outcomes
- 11.15.3 Collaborators
- 11.16 JNJ-42847922
- 11.16.1 Drug Description
- 11.16.2 Outcomes
- 11.17 REM0046127
- 11.17.1 Drug Description
- 11.17.2 Outcomes
- 11.18 Bryostatin 1
- 11.18.1 Drug Description
- 11.18.2 Outcomes
- 11.18.3 Collaborators
- 11.19 NanoLithiumÆ NP03
- 11.19.1 Drug Description
- 11.19.2 Outcomes
- 11.20 AstroStem
- 11.20.1 Drug Description
- 11.20.2 Outcomes
- 11.21 Gantenerumab
- 11.21.1 Drug Description
- 11.21.2 Outcomes
- 11.22 Semorinemab
- 11.22.1 Drug Description
- 11.22.1 Outcomes
- 11.23 Obicetrapib
- 11.23.1 Drug Description
- 11.23.2 Outcomes
- 11.24 ALZ-801
- 11.24.1 Drug Description
- 11.24.2 Outcomes
- 11.25 CY6463
- 11.25.1 Drug Description
- 11.25.2 Outcomes
- 11.26 Crenezumab
- 11.26.1 Drug Description
- 11.26.2 Outcomes
- 11.26.3 Collaborators
- 11.27 T3D-959
- 11.27.1 Drug Description
- 11.27.2 Outcomes
- 11.28 PMZ-1620
- 11.28.1 Drug Description
- 11.28.2 Outcomes
- 11.29 GV1001
- 11.29.1 Drug Description
- 11.29.2 Outcomes
- 11.30 ACZ885
- 11.30.1 Drug Description
- 11.30.2 Outcomes
- 11.31 PQ912
- 11.31.1 Drug Description
- 11.31.2 Outcomes
- 11.31.3 Collaborators
- 11.32 APH-1105
- 11.32.1 Drug Description
- 11.32.2 Outcomes
- 11.33 SLS-005
- 11.33.1 Drug Description
- 11.33.2 Outcomes
- 11.33.3 Collaborators
- 11.34 Flos gossypii flavonoids
- 11.34.1 Drug Description
- 11.34.2 Outcomes
- 11.34.3 Collaborators
- 11.35 Human Mesenchymal Stem cells (MSCs),
- 11.35.1 Drug Description
- 11.35.2 Outcomes
- 11.36 JNJ-63733657
- 11.36.1 Drug Description
- 11.36.2 Outcomes
- 11.37 IGC-AD1
- 11.37.1 Drug Description
- 11.37.2 Outcomes
- 11.38 TW001
- 11.38.1 Drug Description
- 11.38.2 Outcomes
- 11.39 ABvac40
- 11.39.1 Drug Description
- 11.39.2 Outcomes
12. Phase II/III therapeutics Overview
- 12.1 Tricaprilin
- 12.1.1 Drug Description
- 12.1.2 Outcomes
- 12.2 ANAVEX2-73
- 12.2.1 Drug Description
- 12.2.3 Outcomes
- 12.3 Piromelatine
- 12.3.1 Drug Description
- 12.3.2 Outcomes
- 12.3.3 Collaborators
- 12.4 AGB101
- 12.4.1 Drug Description
- 12.4.2 Outcomes
- 12.4.3 Collaborators
13. Phase III therapeutics Overview
- 13.1 Simufilam
- 13.1.1 Drug Description
- 13.1.2 Outcomes
- 13.1.3 Collaborators
- 13.2 ATH-1017
- 13.2.1 Drug Description
- 13.2.2 Outcomes
- 13.3 Lecanemab
- 13.3.1 Drug Description
- 13.3.2 Outcomes
- 13.3.3 Collaborators
- 13.4 Nilotinib BE
- 13.4.1 Drug Description
- 13.4.2 Outcomes
- 13.4.3 Collaborators
- 13.5 Brexpiprazole
- 13.5.1 Drug Description
- 13.5.2 Outcomes
- 13.5.3 Collaborators
- 13.6 Masitinib
- 13.6.1 Drug Description
- 13.6.2 Outcomes
- 13.7 Remternetug
- 13.7.1 Drug Description
- 13.7.2 Outcomes
- 13.8 Donanemab
- 13.8.1 Drug Description
- 13.8.2 Outcomes
- 13.9 NE3107
- 13.9.1 Drug Description
- 13.9.2 Outcomes
- 13.10 Gantenerumab
- 13.10.1 Drug Description
- 13.10.2 Outcomes
- 13.11 GV-971
- 13.11.1 Drug Description
- 13.11.2 Outcomes
- 13.12 Aducanumab
- 13.12.1 Drug Description
- 13.12.2 Outcomes
- 13.13 TRx0237
- 13.13.1 Drug Description
- 13.13.2 Outcomes
- 13.14 Semagludtide
- 13.14.1 Drug Description
- 13.14.2 Outcomes
- 13.15 BPDO-1603
- 13.15.1 Drug Description
- 13.15.2 Outcomes
- 13.16 AR1001
- 13.16.1 Drug Description
- 13.16.2 Outcomes
- 13.17 KarXT
- 13.17.1 Drug Description
- 13.17.2 Outcomes
- 13.18 AXS-05
- 13.18.1 Drug Description
- 13.18.2 Outcomes
14. Phase IV therapeutics Overview
- 14.1 Choline Alfoscerate
- 14.1.1 Drug Description
- 14.1.2 Outcomes
- 14.2 Ebicomb
- 14.2.1 Drug Description
- 14.2.2 Outcomes
- 14.3 Rivastigmine
- 14.3.1 Drug Description
- 14.3.2 Outcomes
- 14.4 GV-971
- 14.4.1 Drug Description
- 14.4.2 Outcomes
15. Preclinical Phase therapeutics Overview
- 15.1 PMN310
- 15.1.1 Drug Description
- 15.1.2 Outcomes
- 15.1.3 Collaborators
- 15.2 PRX123
- 15.2.1 Drug Description
- 15.2.2 Outcomes
16. Pipeline analysis, By molecule type
- 16.1 Alzheimer's Therapeutics Comparative Review, by Molecule type
17. Pipeline Analysis, By Route of Administration
- 17.1 Alzheimer's Therapeutics Comparative Review, By Route of Administration
List of Figures
List of Figures
Fig 1: Alzheimer's Disease Therapeutics for next 7 years (in USD Millions)
Fig 2: Alzheimer's Disease Therapeutics Size, By Sales Channel, 2018 & 2028 (USD Million)
Fig 3: Alzheimer's Hospitalization Statistics, 2022 (per 1,000 Medicare Beneficiaries)
Fig 4: Eli Lilly and Company Revenues, 2019-2021 (USD Million)
Fig 5: Eli Lilly and Company Revenue, By Business Segments, 2021 (%)
Fig 6: Eli Lilly and Company Revenue, By Geographical Segments, 2021 (%)
Fig 7: Eisai Co., Revenues, 2019-2021 (USD Million)
Fig 8: Eisai Co., Revenue, By Business Segments, 2021 (%)
Fig 9: Eisai Co., Revenue, By Geographical Segments, 2021 (%)
Fig 10: Johnson & Johnson Revenues, 2019-2021 (USD Million)
Fig 11: J&J Revenue, By Business Segments, 2021 (%)
Fig 12: J&J Revenue, By Geographical Segments, 2021 (%)
Fig 13: Otsuka Pharmaceuticals Revenues, 2019-2021 (USD Million)
Fig 14: Otsuka Revenue, By Business Segments, 2021 (%)
Fig 15: Otsuka Revenue, By Business Segments, 2020 (%)
Fig 16: H. Lundbeck Revenues, 2019-2021 (USD Million)
Fig 17: H. Lundbeck Revenue, By Business Segment by Product, 2021 (%)
Fig 18: H. Lundbeck Revenue, By Geographical Segments, 2021 (%)
Fig 19: Novartis Revenues, 2019-2021 (USD million)
Fig 20: Novartis Revenue, By Business Segments, 2021 (%)
Fig 21: Novartis Revenue, By Geographic Segments, 2021 (%)
Fig 22: Merck & Co., Inc. Revenues, 2019-2021 (USD Million)
Fig 23: Merck & Co., Inc. Revenue, By Business Segments, 2021 (%)
Fig 24: Merck & Co., Inc. Revenue, By Geographic segment, 2021 (%)
Fig 25: Biogen Revenues, 2019-2021 (USD Million)
Fig 26: Biogen Revenue, By Business Segments- By Products, 2021 (%)
Fig 27: Biogen Revenue, By Geographic Segments, 2021 (%)
Fig 28: Global Prevalence of Alzheimer's disease and other dementias, 2017-2019 (Millions)
Fig 29: Global Incidence of Alzheimer's disease and other dementias, 2017-2019 (Millions)
Fig 30: Global Prevalence of Alzheimer's disease and other dementias, In Females, 2017-2019 (Millions)
Fig 31: Global Prevalence of Alzheimer's disease and other dementias, In Males, 2017-2019 (Millions)
Fig 32: Global Diabetes data report 2000 o 2045(E), (in thousands)
Fig 33: Estimated global prevalence and numbers of people with obesity and severe obesity in 2020, 2025 (E) and 2030 (E)
Fig 34: Estimated prevalence of obesity amongst women in, 2030 (E)
Fig 35: Estimated prevalence of obesity amongst men in, 2030 (E)
Fig.36: Therapeutics in Phase I, by Molecule type
Fig.37: Therapeutics in Phase I/II by Molecule type
Fig. 38: Therapeutics in Phase II by Molecule type
Fig.39: Therapeutics in Phase II/III by Molecule type
Fig. 40: Therapeutics in Phase III by Molecule type
Fig.41: Therapeutics in Phase IV by Molecule type
Fig. 42: Therapeutics in Preclinical Phase, by Molecule type
List of Tables
Table 1: Key Company Financials, 2019-2021
Table 2: Key Company Financials, 2019-2021
Table 3: Key Company Financials, 2019-2021
Table 4: Key Company Financials, 2019-2021
Table 5: Key Company Financials, 2019-2021
Table 6: Key Company Financials, 2019-2021
Table 7: Key Company Financials, 2019-2021
Table 8: Key Company Financials, 2019-2021
Table 9: Total Drugs in Alzheimeris Disease Pipeline
Table 10: Total Alzheimeris Disease Drugs in Phase I of Pipeline
Table 11: Total Alzheimeris Disease Drugs in Phase I/II of Pipeline
Table 12: Total Alzheimeris Disease Drugs in Phase II of Pipeline
Table 13: Total Alzheimeris Disease Drugs in Phase II/III of Pipeline
Table 14: Total Alzheimeris Disease Drugs in Phase III of Pipeline
Table 15: Total Alzheimeris Disease Drugs in Phase IV of Pipeline
Table 16: Total Alzheimeris Disease Drugs in Preclinical Phase of Pipeline
